PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com
DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2014/03/11 - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DNA methylation is a major epigenetic modification which plays an important role in controlling gene expression, differentiation and embryonic development. This covalent modification of DNA in mammals is catalyzed by a family of enzymes called methyltransferases.

Methylation abnormalities were identified in both low and high-grade malignancies, supporting the idea that methylation changes can be an early event in tumor progression. Certain tumor types, like colon, glioma, and acute myeloid leukemia, display significantly higher frequency of aberrant methylation events. Therefore, methyltransferases, including DNMT1, 3a and 3b are involved in the progression of many malignant tumors and small compounds inhibiting these enzymes can be used for cancer treatment.

OTAVA Ltd (otavachemicals.com) offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b. Both libraries comprise drug-like compounds only. DNMT1 focused library comprises 503 compounds and DNMT3b targeted library 1320 compounds. The libraries were designed with virtual screening of Drug-like Green Collection. The results of virtual screening were validated with a reference set of known DNMT inhibitors obtained from ChemblDB. Final selection of compounds has been made with inspection of intermolecular hydrogen bonds of ligands with crucial active site’s residues taken from literature reviews, docking score cut-off filtering and exclusion of predicted DNMT1 and DNMT3b cross-binders. Also, 3D pharmacophore model consisting of two hydrogen bond donors, two hydrogen bond acceptors and a hydrophobic region has been applied during the selection.

These libraries provide an excellent basis for development of novel cancer therapeutics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andrey Dmytrenko - OtavaChemicals.com 
416-549-8030 eurasia[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)